In a small study of pediatric patients treated with L-asparaginase-based therapy, levels of protein C, S and vitamin K-dependent factors (such as factors IX and X) of eight patients with thrombosis were compared with those of nine patients without any thrombosis. Zatebradine hydrochloride agent, the use of L-asparaginase has several potential toxicities including the risk of thrombosis [8C10]. In this review, we summarize the key studies on L-asparaginase-related venous thromboembolism (VTE) in patients with ALL with a focus on identification of high-risk patients, approaches to prevent VTE and management of patients who develop VTE. Epidemiology The incidence of VTE in ALL patients has been reported to vary from 1 to 36% depending upon the age group of the patients, study designs, treatment protocols, symptomatic thromboembolism versus detection with screening radiography [10C12]. Caruso asparaginase was associated with a greater likelihood of coagulation abnormalities (defined as any clinical or biologic abnormality, e.g., hypofibrinogenemia requiring a modification of chemotherapy or supportive care) [25]. In another small study (n = 20), the use of asparaginase was associated with a higher risk of decline in protein C level below 70%, compared with Erwinia asparaginase (50 vs 0%; p = 0.03) [27]. The use of L-asparaginase encapsulated within erythrocytes, compared with the native form of the enzyme, is thought to allow gradual serum asparagine depletion with lower doses. This is speculated to be associated with a lower risk of toxicities including thrombotic complications [28]; however, it remains to be established in larger studies. The use of CVC may be a potential risk factor for site-specific thrombotic events with 25 out of 91 VTE events (27.5%) associated with CVC in the Caruso study; CVC-associated thrombosis accounted for more than half of non-CNS thrombosis. Although unclear in asparaginase-related VTE, the risk of line-related thrombosis in general appears to be higher with the use of peripherally inserted central catheter than CVC [29]. The use of anthracycline as well as prednisone (vs dexamethasone), particularly during postinduction therapy, were other potential risk factors [12]. In another pediatric study, all of the CNS thromboses occurred during the induction phase and were associated with the use of prednisone as steroid [21]. Prior studies have assessed the presence of any correlation between the level of coagulation proteins or inherited thrombophilia and the risk of L-asparaginase-related thrombosis. In a small study of pediatric patients treated with L-asparaginase-based therapy, levels of protein C, S and vitamin K-dependent factors (such as factors IX and X) of eight patients with thrombosis were compared with those of nine patients without any thrombosis. The frequency of protein C deficiency (37 vs 33%; p = 0.38) and protein S deficiency (83 vs 28%; p = 0.10) was numerically different but statistically similar between patients with versus without thrombosis. The lower levels of protein C and S were also associated with reduced levels of factors IX and X. Furthermore, the ratio of protein C and S to each other and to factors IX and X was similar in the two groups [30]. Although this study demonstrated no clear evidence of the reduced levels of these proteins in identifying at-risk patients, this may Zatebradine hydrochloride have been related to small sample size. An Israeli pediatric study (n = 41) utilizing enoxaparin prophylaxis (discussed later in detail) demonstrated a high incidence of genetic thrombophilia in 27 children (11% prothrombin G20210A and 18% factor V Leiden), who were Arabs and Jews in ethnic origin; Rabbit polyclonal to IL27RA however, no one had any VTE [31]. Another underpowered prospective trial Zatebradine hydrochloride of 85 pediatric patients demonstrated no significant association between thrombosis and the presence of factor V Leiden mutation, prothrombin gene 20210A and antiphospholipid antibodies [32]. An Italian study of 48 children demonstrated a numerically higher prevalence of factor V Leiden (20 vs 3C7%; p-value unavailable) and prothrombin mutation (10 vs 1C3%; p-value unavailable) in the ALL patients with VTE, as compared with the general population [22]. In the Dana-Farber study, the prevalence of activated protein C resistance (9% of 23 patients tested) and factor V Leiden mutation (4%) was felt to be similar to that expected in the general population [11]. In an adult study, none of the patients with VTE who underwent thrombophilia testing (54% of 24), were found to have factor V Leiden mutation or prothrombin gene 20210A [13]. The aforementioned meta-analysis assessed the impact of genetic thrombophilia in 557 children; the presence of genetic prothrombotic abnormalities was similar to that of Zatebradine hydrochloride general population. In pooled analysis, the presence of.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed